IQVIA Institute Report: The Global Use of Medicines 2022
The IQVIA institute has released a report on global spending on medicines medicine during 2021 and projections up until 2026. [...]
Insider Trading Charges Filed Against University of Chicago Professor
University of Chicago professor Daniel Catenacci, MD has been charged with insider trading regarding his actions during a phase [...]
Free eBook: Revisiting Rare Disease
Rare Disease Advisor is now offering a free eBook that shines a light on the state of the rare disease [...]
Drug Makers Raise Prices of Hundreds of Medications by 4.9% for 2022
Data from 46Brooklyn Research shows that drugmakers have raised the cost of 460 drugs by a median of 4.9%. These [...]
Abbvie Calls for U.S. International Trade Commission Investigation of Alvotech’s Humira Biosimilar
The manufacturer Abbvie has formally asked the U.S. International Trade Commission to investigate Alvotech’s lower-cost Humira biosimilar. Alvotech has faced [...]
Healthcare Spending by the Numbers: New NHE Data
National Health Expenditures (NHE) data was recently released by the Centers for Medicare & Medicaid Services (CMS) for 2020. The [...]
NICE’s 5-Year Strategy Signals a More Collaborative Approach.
The UK’s National Institute for Health and Care Excellence (NICE) new health technology assessment manual signals a push towards greater [...]
Webinar: Japan’s Regulatory Requirements for Cell and Gene Therapy
On the latest C-Cast mini-webinar by CMIC, Dr. Kazuhiro Fukuta, Senior Consultant and the Head of Regenerative Medicine Group in [...]
Express Scripts Integrates Member Benefits and Rx Discount Card Pricing
Express Scripts has unveiled its new Right Price program, which lets members effortlessly get savings on prescription drugs by automatically [...]
Unsubstantiated Drug-Price Hikes Identified by ICER
An ICER report examining the top ten drugs with 2020 price hikes found that a staggering seven out of ten [...]
Webinar: Biden, Congress, and Drug Prices
Drug pricing is being targeted by both the Biden administration and congress, according to a webinar now available on Research [...]
Value-based Pricing Programs Given Renewed Focus by Pfizer and Takeda
Value-based pricing and reimbursement models are not common in the United States, but this may change after recent programs by [...]
Possible Impact of the Build Back Better Plan on Chronic Illness – Patients Rising Podcast
With the Build Back Better Act having passed the House, some question how changes to the bill in the Senate [...]
Will Rob Califf’s industry ties sink his FDA commissioner nomination?
Dr. Rob Califf’s extensive industry ties cast uncertainty on his nomination for FDA commissioner. The nominee’s financial disclosures, released this [...]
Navigating the FDA Real-Time Oncology Review Process for Sponsors
Started in 2018, the FDA’s “Real-Time Oncology Review (ROTR)” project gives sponsors a head start on the application review [...]
“Specialty Pharmacy’s Post-Pandemic Outlook” Asembia 2021 Keynote Recap
The future of specialty pharmacy in the post-pandemic world was the topic of the October 27th keynote sessions at Asembia [...]
Changing Dynamics Between NICE and Pharmaceutical Industry
Recent shifts in the UK’s National Institute for Health and Care Excellence’s (NICE) approach to health technology assessment (HTA) are [...]
Panalgo and HealthEconomics.Com Host Webinar on Successful ICER Strategies
Panalgo and HealthEconomics.Com hosted a webinar detailing strategies that lead to successful evaluation by the Institute for Clinical and Economic [...]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
Flatiron ResearchX On-Demand Webinar on RWE in Regulatory Submissions
Flatiron ResearchX invited real world evidence (RWE) and pharma leaders to discuss how RWE impacts submissions to regulatory bodies. Available [...]
Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
Updated Promising Zone Design Improves Workflow and Clinical Trial Design for Biotechs
Promising Zone Design was first introduced a decade ago as a method to estimate sample size. The method is still [...]
Will Mark Cuban’s PBM Deliver on Pricing Promises?
Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the [...]